Monte Rosa Therapeutics Inc (GLUE)
EBITDA Growth
-360.09%
Quarterly · Period ending:
GLUE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-360.09%period ending
Latest reported-360.09%period ending
GLUE Quarterly EBITDA YoY % (-165.61% → -360.09%)
Year-over-year change
High-resolution chart · PNG
GLUE ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -360.0936% | |
| -185.2618% | |
| -349.0545% | |
| -29.8732% | |
| 67.9584% | |
| 265.9164% | |
| 156.1983% | |
| 38.2774% | |
| 16.6652% | |
| 2.9106% | |
| -5.7754% | |
| -33.6618% | |
| -31.3409% | |
| -33.2542% | |
| -31.2889% | |
| -36.51% | |
| -42.6023% | |
| -106.4025% | |
| -93.2127% | |
| -209.815% | |
| -236.9271% | |
| -165.6102% |